{
  "id": 28442,
  "title": "Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate",
  "url": "https://urgent.news/2026/07/30/latigo-reports-positive-phase-iib-data-for-non-opioid-acute-pain",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-30T13:00:14.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/translational-medicine/latigo-reports-positive-phase-iib-data-for-non-opioid-acute-pain-candidate/"
  },
  "original_language": "en",
  "account": null,
  "summary": "LTG-001 achieved the primary endpoint of the Phase IIb LTG-001-010 trial (NCT07102459) by achieving better-than-placebo scores in the time-weighted sum of the pain-intensity difference (SPID) over the 48-hour treatment period (SPID48), based on the 0-10 range of scores of the Numeric Pain Rating Scale, with higher SPID48 values indicating greater pain reduction. The post Latigo Reports Positive…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}